[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604760":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":7,"responsibleParty":8,"collaborators":7,"id":12,"slug":7,"hasResults":13,"nctId":14,"briefTitle":15,"officialTitle":15,"acronym":7,"eligibilityCriteria":16,"healthyVolunteers":13,"sex":17,"minAge":18,"maxAge":7,"enrollmentInfo":19,"targetDuration":7,"studyType":22,"phases":7,"briefSummary":23,"conditions":24,"keywords":7,"overallStatus":26,"whyStopped":7,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":7},{"fullName":5,"class":6},"Shandong University","OTHER",null,{"type":9,"investigatorFullName":10,"investigatorTitle":11,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Beihua Kong","archiater","100604760",false,"NCT07153705","OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer","Inclusion criteria:\n\n1. Women over 18 years old;\n2. Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;\n3. ECOG \\\u003C 2;\n4. The expected survival period exceeds 6 months;\n5. CA125 ≤ 35 U\u002Fml before initial treatment;\n6. Undergo surgery and adjuvant chemotherapy;\n7. The period between diagnosis and enrollment does not exceed 8 weeks;\n8. Be willing to provide blood samples for OCS testing during the research process;\n9. Sign the informed consent form.\n\nExclusion criteria\n\n1. Have had other malignant tumors within the last five years;\n2. Have received any treatment for ovarian cancer;\n3. Benign ovarian mass;\n4. Non-primary ovarian tumors;\n5. Combined with other malignant tumors;\n6. Patients receiving neoadjuvant therapy;\n7. Pregnancy.","FEMALE","18 Years",{"count":20,"type":21},32,"ESTIMATED","OBSERVATIONAL","To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.",[25],"Ovarian Cancer","NOT_YET_RECRUITING","2025-08-26",{"date":29,"type":30},"2025-09-04","ACTUAL",{"date":32,"type":21},"2025-09-01",{"date":34,"type":21},"2026-04-01",{"name":10,"class":6}]